Strategies for laboratory HIV testing: an examination of alternative approaches not requiring Western blot.
Advances in laboratory tests for antibodies to human immunodeficiency virus (HIV) have permitted the development of alternative HIV testing strategies that do not require use of the Western blot approach. Three strategies are proposed. In strategy I, sera are tested for HIV antibody using an enzyme-linked immunosorbent assay (ELISA)/rapid/simple (ERS) test; in strategy II, sera reactive in an initial ERS test are retested using a second ERS test; strategy III involves retesting with a third ERS test all sera reactive in two previous ERS tests. Where the objective is identification of asymptomatic HIV-infected individuals, strategy III is proposed where HIV prevalences in the study population are < or = 10%, and strategy II at prevalences > 10%. Strategy II is recommended where the diagnosis of HIV-related disease requires HIV testing. For serosurveillance, strategy II is recommended if the prevalence is < or = 10%, and strategy I if the prevalences are > 10%. Use of strategy I is recommended for transfusion and transplantation safety, at any prevalence. Lower-cost laboratory HIV testing will permit such testing to become more widely available.
Sato
P A
PA
Evaluation Unit, WHO Global Programme on AIDS, Geneva, Switzerland.
Maskill
W J
WJ
Tamashiro
H
H
Heymann
D L
DL
D015492:AIDS Serodiagnosis / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D015528:HIV Seroprevalence; D015497:HIV-1 / Q000276:immunology; D015498:HIV-2 / Q000276:immunology; D006801:Humans; D011237:Predictive Value of Tests; D011786:Quality Control; D012680:Sensitivity and Specificity; D016036:Seroepidemiologic Studies